Mammography Innovations: Are we Detecting Breast cancer early enough?

Published Date: 27 Dec 2024

Share: Facebook X LinkedIn

Breast cancer remains one of the cancers that are prevalent among women all over the world. By 2020, the world’s leading health care institution, the World Health Organization reported that breast cancer alone contributed to 2.3 million new cases and 685,000 deaths. There is more indication that mammography screening enhances early detection and takes the five-year survival rate for localized breast cancer at 99% as opposed to 28% for the advanced stage. With these compelling statistics, the question arises: are current innovations in mammography providing accurate detection efficiently?

Mammography Innovations: Are we Detecting Breast cancer early enough?

The role of Mammography in Breast cancer

Mammography has been the gold standard modality for breast cancer screening for many years. Mammograms employ low-dose X-rays to identify possible cancers by detecting unusual formations and changes in the breast tissues. Screening is especially beneficial for tumors that cannot yet be palpated and is now considered an essential component of the preventive health care package for women of postmenopausal age.

What Innovations have been made in Mammography technology?

Recent developments in mammography have improved the precision and effectiveness of breast cancer detection. Some of the ground-breaking inventions in mammography are listed below:

3D Mammography (Digital Breast Tomosynthesis): One of the most important innovations is digital breast tomosynthesis, which reconstructs images of the woman’s breast tissue in cross-sectional planes. In comparison to 2D or conventional mammography, this data increases low contrast and reinforms overlapping tissue artifacts and increments in detection parameters. It shows that the use of 3D mammography leads to a 27% increase in the percentage of detected cancer cases that could not be observed with the help of 2D mammography, which decreases false-positive recalls by 15%; however, such technologies require more time and money to provide, which public could not always afford.

Contrast-Enhanced Mammography (CEM): This technique utilizes a contrast agent to bring out features of tissues with high blood flow, a feature of cancerous tissues. CEM has demonstrated potential in improving tumor visibility mostly in mammography-dense breast tissue; given literature suggests that CEM achieves comparable accuracy to MRI at a considerably lower cost and shorter examination time. Nevertheless, the importance of the use of contrast agents is that it may not work well for all the patients especially those who have various diseases such as kidney diseases.

AI in Mammography: Artificial intelligence is proving to be instrumental in screenings and bettering the chances of detecting diseases related to the mammary gland. Processing large amounts of data, AI algorithms used for cancer detection and diagnosis are more accurate than human though experienced radiologists. A paper in The Lancet Digital Health said that AI systems for detecting breast cancer performed as effectively as radiologists while cutting false positives by 9.4%. In addition to detection, AI can combine the mammography outcomes with the patient’s history and risk factors to improve the clinicians’ decisions.

Automated Breast Ultrasound: ABUS provides an adjunct imaging modality. Compared to other methods, ABUS gives detailed images of growths in the messy areas, and hence, comes with higher cancer found in these areas. However, the test is not used as a standalone method of screening, and it should be used in conjunction with mammography.

Challenges in early detection

Assuming technological progress in breast cancer detection, there are still several barriers to early diagnosis such as:

Access and Equity: Across the world, there are untimely screening services due to limited access to health care services by many women. The problem is compounded in low-income nations because there is low awareness and few facilities to provide mammography. More, only 26% of eligible women go for mammography in contrast to 73% in developed countries.

Dense Breast Tissue: The risk therefore increases for those women with dense breast tissue, as they are at higher risk of developing both breast cancer and false-negative results. To overcome this challenge, approaches such as 3D mammography and ABUS exist but their utilization by both patients and clinicians is still scarce.

False Positives and Overdiagnosis: A false positive result is stressful and causes unneeded biopsies and treatments. On the other hand, there is overdiagnosis—the identification of malignant diseases that are unlikely to be lethal—raises questions about over-intervention. While systems such as AI and CEM are moderating these problems, they are not perfect.

Are we detecting Breast cancer early enough?

More progress has been made over the recent past but efforts can still be made. While early detection rates are increasing in many countries, access to screening, awareness about that access, and the technologies used to provide and access the screening also remain inadequate in many places. For example, breast cancer mortality is 0.5% or less in developed countries while in developing countries it is 20% or more due to late-stage presentation. The key to universal early detection lies in providing more opportunities for advanced technologies, enhancing people’s knowledge of the need to undergo screening as frequently as possible, and expanding research into improved and advanced smaller, finer, and even cheaper instruments.

The Future aspects:

The future of mammography has the field utilizing various modalities that consist of targeted screening, better imaging, and strong integration of artificial intelligent tools to provide accurate and early detection of breast cancer. One-way screening programs are going to be critical in the development of flexible screening periods and methods regarding personal risk factors including family history and breast tissue density among others and lifestyle. It has been designed to enhance early diagnosis possibilities, avoiding overdiagnosis and additional unnecessary interventions, and with more focus on patients’ needs. New findings based on advanced technologies that have not been validated clinically, including molecular breast imaging (MBI), the technology scans for gamma rays from cancer cells at the molecular level. This method offers the highest precision in detecting malignancies as compared with other methods more so in women with ample breast tissue where the other modalities prove most ineffective. Despite the huge potential of MBI its usage and optimization require further investigation and the accessibility for a wider audience needs to be created.

It will be important for researchers, clinicians, and policymakers to work together to overcome the implementation challenges. Whenever there is adoption of learning technologies, training, infrastructure as well as public awareness and campaigns should also be provided to facilitate adequate use and effectiveness. In conclusion, it rests on society and policymakers to fully capitalize on this progress and bring the value of new technologies to mammography results to women all over the world.

Conclusion

Mammography has grown from its rudimentary conception to more advanced methods of examining the ailment in the breast, including 3D imaging, integration of artificial intelligence, and portable units for capturing early diagnosis. But translating these advancements to all women across geography and all sectors of society is still a major work in progress. Through the adoption of these innovations as well as addressing the disparities present within health systems, we stand a better chance of enhancing early detection, increasing the number of lives saved for women and girls across the globe.

 

Maximize your value and knowledge with our 5 Reports-in-1 Bundle - over 40% off!

Our analysts are ready to help you immediately.